Diltiazem chemical structure
Find information on thousands of medical conditions and prescription drugs.

Tiazac

Diltiazem is a member of the group of drugs known as calcium channel blockers, used in the treatment of hypertension or angina. It is marketed under several brand names, including Cardizem, Cartia XT, and Tiazac.it is a class 3 anti anginal drug.it incites very minimal reflex sympathetic changes.


Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Court Rules in Favor of Biovail in Tiazac Class Actions
From Business Wire, 4/4/05

TORONTO -- Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that a United States District Judge for the District of Columbia has granted Biovail's motions for summary judgment, thereby dismissing complaints in two related putative class-action cases asserting antitrust claims by purchasers of Biovail's Tiazac(R) product. E[acute accent]The complaints, launched in 2001 and 2003, alleged that Biovail's listing with the U.S. Food and Drug Administration (FDA) of a patent for Tiazac(R) improperly delayed the entry of a competing generic product. Plaintiffs further alleged that the delay in entry of a generic product into the market caused them to pay a premium to purchase Biovail's brand-name product. E[acute accent]In its summary judgment motion, Biovail contended that the reason why the owner of generic Tiazac(R) had not marketed its product on a timely basis was due to its inability to obtain final FDA approval, rather than through any action or omission on the part of Biovail. E[acute accent]In granting Biovail's motions for summary judgment, the Court agreed with Biovail's position that, in light of the evidence and facts pleaded, the plaintiffs had been unable to prove that they had suffered any damages for which Biovail could be responsible.

E[acute accent]About Tiazac(R)

E[acute accent]Tiazac(R) (diltiazem) belongs to a classification of drugs known as calcium channel blockers currently indicated for the treatment of hypertension and angina. Tiazac(R) works by slowing the heart rate, and by relaxing and widening blood vessels (arteries), which reduces blood pressure. Widening of the coronary arteries also increases the amount of blood reaching the heart, which can reduce the symptoms of angina.

E[acute accent]About Biovail Corporation

E[acute accent]Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of pharmaceutical products utilizing advanced drug-delivery technologies. For more information about Biovail, visit the company's Web site at www.biovail.com. E[acute accent]For further information, please contact Ken Howling at 905-286-3000 or send inquiries to ir@biovail.com.

E[acute accent]"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995

E[acute accent]To the extent any statements made in this release contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future events. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements include, but are not necessarily limited to, risks and uncertainties, including the difficulty of predicting U.S. Food and Drug Administration and Canadian Therapeutic Products Directorate approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished products, the regulatory environment, the outcome of legal proceedings, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission and the Ontario Securities Commission. Biovail undertakes no obligation to update or revise any forward-looking statement.

COPYRIGHT 2005 Business Wire
COPYRIGHT 2005 Gale Group

Return to Tiazac
Home Contact Resources Exchange Links ebay